McMillan Office’s Quest Diagnostics DGX Stock Holding History

McMillan Office’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$103K	Hold	486	–	–	0.01%	241
2026 Q1	$95.2K	Hold	486	–	–	0.01%	242
2025 Q4	$84.3K	Buy	+486	New	+$88.5K	0.01%	251

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

McMillan Office's DGX Position: Q2 2026 in Review

McMillan Office held its Quest Diagnostics (DGX) position steady in Q2 2026 at 486 shares worth $103K. The position accounts for 0.01% of the portfolio, ranked #241.

McMillan Office first reported a position in DGX in Q4 2025 and has held it in 3 quarters since. 1,105 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

McMillan Office held 486 shares of Quest Diagnostics worth $103K as of Q2 2026.
McMillan Office left its Quest Diagnostics share count unchanged in Q2 2026.
Quest Diagnostics made up 0.01% of McMillan Office's portfolio in Q2 2026, its #241 holding.
McMillan Office first reported a position in Quest Diagnostics in Q4 2025 and has held it in 3 quarters since.
1,105 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on McMillan Office's 13F filing for Q2 2026, filed 13 Aug 2026.